Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab

Dermatology

Volumn 218, Issue 3, 2009, Pages 237-245

  Pfütze, Martin ^a   Eming, Rüdiger ^a   Kneisel, Andrea ^a   Kuhlmann, Uwe ^a   Hoyer, Joachim ^a   Hertl, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Autoantibody, antidesmoglein; Autoimmune bullous skin disorders intensity score; Immunoadsorption; Pemphigus; Rituximab

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; DESMOGLEIN 1; DESMOGLEIN 2; DESMOGLEIN ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADJUVANT THERAPY; ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOADSORPTION; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MOUTH MUCOSA; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCALP; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; DESMOGLEIN 1; DESMOGLEIN 3; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGED; PEMPHIGUS;

EID: 62049083542     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187431     Document Type: Article

References (34)

1. Amagai M, Klaus-Kovtun V, Stanley JR: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991;67:869-877.
2. Hertl M, Veldman C: T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev 2003;2:278-283.
3. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR: Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461-468.
4. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999;40:167-170.
5. Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S, Shimizu N, Nishikawa T: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997;159:2010-2017.
6. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T: Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002;147:261-265.
7. Arin MJ, Hunzelmann N: Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus - an update. Eur J Dermatol 2005;15:224-230.
8. Eming R, Hertl M: Immunoadsorption in pemphigus. Autoimmunity 2006;39:609-616.
9. Cotterill JA, Barker DJ, Millard LG: Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978;98:243.
10. Braun N, Bosch T: Immunoadsorption, current status and future developments. Expert Opin Investig Drugs 2000;9:2017-2038.
11. Hershko AY, Naparstek Y: Removal of pathogenic autoantibodies by immunoadsorption. Ann NY Acad Sci 2000;1051:635-646.
12. Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Hertl M, Hofmann SC, Karlhofer F, Kautz O, Nitschke M, Opitz A, Quist S, Rose C, Schanz S, Schmidt E, Shimanovich I, Michael M, Ziller F: Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007;5:881-887.
13. Edwards JC, Cambridge G: B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
14. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke S: Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008;6:366-373.
15. Pfütze M, Niedermeier A, Hertl M, Eming R: Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol 2007;17:4-11.
16. Eming R, Niedermeier A, Pfütze M, Jacobi A, Hertl M: Treating autoimmune bullous skin disorders with biologics;in Boehncke WH, Radeke H (eds): Biologics in General Medicine. Berlin, Springer Science + Business Media, 2007.
17. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn J, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP: Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58:1043-1046.
18. Müller R, Svoboda V, Wenzel E, Gebert S, Hunzelmann N, Müller HH, Hertl M: IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris. Exp Dermatol 2006;15:606-614.
19. Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, Hertl M: Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006;212:177-187.
20. Lüftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M: Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophanlinked polyvinylalcohol adsorber. Br J Dermatol 2003;149:598-605.
21. Schmidt E, Klinker E, Opitz A, Zillikens D: Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003;148:1222-1229.
22. Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Bröcker EB, Goebeler M, Zillikens D: Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006;31:768-774.
23. Amagai M, Hashimoto T, Shimizu N, Nishikawa T: Adsorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (desmoglein 3) produced by baculovirus. J Clin Invest 1994;94:59-67.
24. Herrero-González JE, Brauns O, Egner R, Zillikens D: Immunoadsorption against two distinct epitopes on human type XVII collagen abolishes dermal-epidermal separation induced in vitro by autoantibodies from pemphigoid gestationis patients. Eur J Immunol 2006;36:1039-1048.
25. Müller R, Svoboda V, Wenzel E, Müller HH, Hertl M: IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Exp Dermatol 2008;17:35-43.
26. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-1779.
27. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P: A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-552.
28. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D: Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008;158:382-388.
29. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M: Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008;128:2850-2858.
30. Shlomchik MJ, Craft JE, Mamula MJ: From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001;1:147-153.
31. Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M: Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol 2003;170:635-642.
32. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, Malmström V, Trollmo C: Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2006;122:62-74.
33. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN: Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123:66-73.
34. Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M: Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 2007;143:192-198.